Rheumatologic serologies: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 28: | Line 28: | ||
| |
| |
||
|- |
|- |
||
| − | |Anti-Ro/ |
+ | |Anti-Ro/SS-A |
| − | |[[Sjögren syndrome]] |
+ | |[[Sjögren syndrome]], neonatal heart block, [[Systemic lupus erythematosus|subacute SLE]] |
| + | | |
||
| + | |- |
||
| + | |Anti-Ro/SS-A 60 kDa |
||
| + | | |
||
| + | | |
||
| + | |- |
||
| + | |Anti-Ro/SS-A 52 kDa |
||
| + | |[[Systemic sclerosis]] and [[SLE]], often with other antibodies present[[CiteRef::hervier2009cl]] |
||
| |
| |
||
|- |
|- |
||
|Anti-La/SSB |
|Anti-La/SSB |
||
| − | |[[Sjögren syndrome]] |
+ | |[[Sjögren syndrome]], sicca syndrome, [[Neonatal lupus|neonatal SLE]] |
| |
| |
||
|- |
|- |
||
| Line 41: | Line 49: | ||
|- |
|- |
||
|Anti-Jo-1 |
|Anti-Jo-1 |
||
| − | |[[Polymyositis]] |
+ | |[[Polymyositis]], [[antisynthetase syndrome]] |
| |
| |
||
|- |
|- |
||
| Line 58: | Line 66: | ||
|Anti-MPO (pANCA) |
|Anti-MPO (pANCA) |
||
|[[Microscopic polyangiitis|MPA]] and [[Eosinophilic granulomatosis with polyangiitis|eGPA]] |
|[[Microscopic polyangiitis|MPA]] and [[Eosinophilic granulomatosis with polyangiitis|eGPA]] |
||
| + | | |
||
| + | |- |
||
| + | |Anti-parietal cell antibodies |
||
| + | |[[Autoimmune gastritis]], [[pernicious anemia]] |
||
| |
| |
||
|} |
|} |
||
Revision as of 11:18, 17 July 2021
| Test | Association | Correlates with dz activity? |
|---|---|---|
| ANA | SLE | No |
| ANA (centromere pattern) | CREST syndrome, SSc, PH | |
| Anti-Smith | SLE (most specific) | No |
| Anti-dsDNA | SLE | Yes, especially renal disease |
| Anti-histone | Drug-induced lupus | |
| Anti-U1-RNP | Mixed CTD | |
| Anti-Ro/SS-A | Sjögren syndrome, neonatal heart block, subacute SLE | |
| Anti-Ro/SS-A 60 kDa | ||
| Anti-Ro/SS-A 52 kDa | Systemic sclerosis and SLE, often with other antibodies present1 | |
| Anti-La/SSB | Sjögren syndrome, sicca syndrome, neonatal SLE | |
| Anti-Scl-70 | SSc and pulmonary fibrosis, dcSSc | |
| Anti-Jo-1 | Polymyositis, antisynthetase syndrome | |
| Anti-CCP | RA (most specific) | |
| Anti-smooth muscle | Autoimmune hepatitis | |
| Anti-PR3 (cANCA) | GPA | |
| Anti-MPO (pANCA) | MPA and eGPA | |
| Anti-parietal cell antibodies | Autoimmune gastritis, pernicious anemia |
References
- ^ B. Hervier, M. Rimbert, F. Colonna, M. A. Hamidou, M. Audrain. Clinical significance of anti-Ro/SSA-52 kDa antibodies--a retrospective monocentric study. Rheumatology. 2009;48(8):964-967. doi:10.1093/rheumatology/kep145.
